metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA) 3
mHCC - 1st line (L1) 10
mHCC - 2nd line (L2) 2
lung cancer : non small cell (NSCLC) 5

antibody–drug conjugate
trastuzumab deruxtecan
chemotherapy
antifolates
pralatrexate
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus BSC
gene alteration target therapy
ALK inhibitors
alectinib
brigatinib
ceritinib
crizotinib
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib
EGFR gene alteration
amivantamab-vmjw
mobocertinib
osimertinib
KRAS gene alteration targeted therapy
adagrasib
sotorasib
MET gene alteration targeted therapy
capmatinib
savolitinib
tepotinib
NTRK gene alteration targeted therapy
entrectinib
larotrectinib
RET gene alteration targeted therapy
pralsetinib
selpercatinib
ROS1 and TRK TKI
repotrectinib
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib alone
afatinib plus BSC
afatinib plus paclitaxel
dacomitinib
erlotinib based treatment
erlotinib alone
erlotinib followed by gemcitabine plus platin
erlotinib plus bevacizumab
erlotinib plus cisplatin and gemcitabine
erlotinib plus gemcitabine
erlotinib plus pemetrexed
erlotinib plus SoC
tivantinib plus erlotinib
gefitinib based treatment
gefitinib alone
gefitinib plus BSC
gefitinib plus pemetrexed plus platin
gefitinib plus SoC
gefitinib plus SoC (rechallenge)
pemetrexed plus platin followed by maintenance gefitinib
SoC followed by gefitinib
icotinib
naquotinib
nimotuzumab based treatment
nimotuzumab plus gefitinib
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
ipilimumab followed by nivolumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
avelumab based treatment
avelumab alone
cemiplimab
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib
durvalumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
pembrolizumab and pemetrexed plus platin
pembrolizumab followed by nab-paclitaxel
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
sugemalimab based treatment
Sugemalimab
sugemalimab plus SoC
Tislelizumab
anti-TIGIT
tiragolumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
VEGF(R) inhibitor
ramucirumab
ramucirumab plus erlotinib
sorafenib
sorafenib and erlotinib
vandetanib

versus all
vs chemotherapy
vs antifolates
vs pemetrexed
vs non platinum-based chemotherapy
vs alkylating agents
vs temozolomide
vs nucleoside analogues (pyrimidine/purine)
vs gemcitabine
vs taxanes
vs docetaxel
vs paclitaxel
vs nab-paclitaxel
vs topoisomerase I inhibitor
vs irinotecan
vs irinotecan plus platin
vs vinca alkaloids
vs vinorelbine
vs vinorelbine and platin
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs docetaxel plus platin
vs gemcitabine plus platin
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs gene alteration target therapy
vs ALK inhibitors
vs crizotinib
vs EGFR gene alteration
vs osimertinib
vs HER inhibitor
vs EGFR inhibitor
vs erlotinib based treatment
vs erlotinib alone
vs Erlotinib plus BSC
vs gemcitabine plus platin followed by erlotinib
vs placebo plus erlotinib
vs gefitinib based treatment
vs gefitinib alone
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs durvalumab based treatment
vs durvalumab alone
vs pembrolizumab based treatment
vs nab-paclitaxel followed by pembrolizumab
vs pembrolizumab alone
vs pembrolizumab (10mg/kg)
vs pembrolizumab plus placebo
vs pembrolizumab plus SoC
vs non active control
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
vs placebo plus BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
vs bevacizumab plus docetaxel
vs bevacizumab plus gemcitabine and platin
vs placebo plus bevacizumab
vs cabozantinib
vs cabozantinib plus erlotinib
vs sorafenib
vs sorafenib and erlotinib
vs sorafenib and gemcitabine

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

CodeBreaK 200, 2022 NCT04303780

sotorasib (n=169) vs. docetaxel (n=151)

randomized controlled trial

Studied treatment

oral sotorasib (960 mg daily)

Control treatment

intravenous docetaxel (75 mg/m2 every 3 weeks)

Patients

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

Method

open-label

Remark

abstract ESMO

powered by vis.js Network